

## REMARKS

The final Office action mailed April 19, 2006 has been received and reviewed. The pending claims were finally rejected. The application is proposed to be amended as previously set forth. All amendments are made without prejudice or disclaimer. Reconsideration is respectfully requested.

Claims 7 and 49 were rejected under 35 U.S.C. 112, first paragraph, because the specification, while admittedly being enabling for a method of mitigating graft rejection and Graft versus Host Disease (GvHD) by administering the 9 amino acid peptide consisting of SEQ ID NO:2, was not thought to reasonably provide enablement for methods of preventing graft rejection or GvHD by administering longer peptides that comprise SEQ ID NO:2.

Although applicants do not agree with this assessment, but in order to expedite processing of the instant application, applicants have amended independent claim 7 to the admittedly enabled subject matter (*i.e.*, a method of inducing tolerance in an HA-1 negative, HLA-A2.1 positive subject to mitigate rejection of an HLA-matched graft and/or Graft versus Host disease, the method comprising repeatedly administering a tolerance-inducing dose of a peptide consisting of SEQ ID NO:2 to the subject). In view of this amendment, applicants believe the rejection to be overcome, and request that it be withdrawn.

Since the proposed amendment merely amends the claims to the admittedly enabled subject matter, no new issues should be raised, and the proposed amendments should be entered.

If questions remain after consideration of the foregoing, the Office is kindly requested to contact applicants' attorney at the address or telephone number given herein.

Respectfully submitted,



Allen C. Turner  
Registration No. 33,041  
Attorney for Applicants  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: August 9, 2006